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Pharmaceutically active compounds (PhACs) and drugs of abuse (DAs) are two
important groups of emerging environmental contaminants that have raised an increasing
interest in the scientiﬁc community. A number of studies revealed their presence
in the environment. This is mainly due to the fact that some compounds are not
efﬁciently removed during wastewater treatment processes, being able to reach surface
and groundwater and subsequently, drinking waters.
This paper reviews the data regarding the levels of pharmaceuticals and illicit
drugs detected in wastewaters and gives an overview of their removal by conventional
treatment technologies (applying activated sludge) as well as advanced treatments such
as membrane bioreactor. The paper also gives an overview of bank ﬁltration practices at
managed aquifer recharge sites and discusses the potential of this approach to mitigate
the contamination by PhACs and DAs.
Keywords: pharmaceutically active compounds; drugs of abuse; conventional activated
sludge treatment; membrane bioreactor; river bank ﬁltration
1. Introduction
Pharmaceutically active substances (PhACs) and drugs of abuse (DAs) are
two classes of new so-called ‘emerging’ contaminants that have raised great
concern in the last years. Their signiﬁcance as trace environmental pollutants
in waterways is due to several reasons: (i) the continuous introduction via
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efﬂuents from sewage treatment facilities and from septic tanks; (ii) they are
developed with the intention of performing a biological effect; (iii) they often
have the same type of physico-chemical behaviour as other harmful xenobiotics
(persistence in order to avoid the substance to be inactive before having a
curing effect, and lipophilicity in order to be able to pass membranes); (iv)
some pharmaceutical substances are used by man in rather large quantities
(i.e. similar to those of many pesticides). Numerous studies revealed their
presence in wastewaters, as well as surface, ground and drinking water. This is
mainly due to the fact that some compounds are not efﬁciently removed during
wastewater treatment processes, being able to reach surface and groundwater
and, subsequently, drinking waters. Although conventional wastewater treatment
plants (WWTPs) can effectively reduce carbon and nitrogen content of raw
sewage, the removal of pharmaceutical residues and DAs is often insufﬁcient
and WWTP efﬂuents are frequently pointed out as the main source of these
microcontaminants.
The objective of this paper is to summarize the data regarding the levels of
pharmaceuticals and illicit drugs detected in wastewaters and to give an overview
of their removal by conventional treatment technologies (applying activated
sludge; CAS) as well as advanced treatments such as membrane bioreactor (MBR)
and riverbank ﬁltration practices at managed aquifer recharge sites.
2. Sources and levels of pharmaceuticals and illicit drugs in wastewaters
Due to their continuous input into the aquatic media through wastewater as
a main point-source, PhACs and DAs are considered to be ‘pseudo-persistent’
contaminants. In a proper evaluation of persistency of a certain compound both
transformation of a compound in the environment and its supply rate should
be taken into consideration. Estimations of pharmaceutical concentration in
sewage have been usually performed by back-calculating the total prescribed
mass from prescription rate data (number of deﬁned daily doses) and excretion
rates, partitioning, biodegradation and the potential hydrolysis of conjugates
(Montforts 2001). However, predictions based on annual sales of drugs are
likely to underestimate the loads of PhACs in the inﬂuents of WWTPs. As
shown by Bound & Voulvoulis (2006), the accuracy of predicted environmental
concentrations is hindered by a shortage of data, both relating to over-the-
counter (OTC) sales of drugs and their fate in WWTPs. In their study, the
measured environmental concentrations were considerably higher than predicted,
suggesting that the areas sampled deviated from the model proposed by the
EMEA (2005). This could be due to regional variations in usage or differences in
WWTP capabilities.
The ubiquity of drugs is related to speciﬁc sales and practices in each country.
For example, antihistamines, analgesics and antidepressants are the families
of drugs with major consumption in Spain, according to the National Health
System. Indeed, in a comprehensive study by Gros et al. (2007), the highest
inﬂuent loads from seven WWTPs were found for non-steroidal anti-inﬂammatory
drugs (NSAIDs), lipid regulators, β-blockers and histamine H1- and H2-receptor
antagonists. Total load of 29 monitored pharmaceuticals ranged from 1 to 5 g d−1
per 1000 inhabitants for inﬂuent wastewater. The results of a study in six
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WWTPs conducted in Italy (Castiglioni et al. 2006a) indicated high inputs of
antibiotics sulphamethoxazole, oﬂoxacin and ciproﬂoxacin, β-blocker atenolol,
antihistaminic ranitidine, diuretics furosemide and hydrochlorothiazide, and
NSAID ibuprofen. Another factor to consider is the outbreak of certain diseases,
such as the case of pandemic of avian inﬂuenza, that would lead, as predicted
for selected US and UK catchments, to high concentrations of antiviral drugs
(especially of oseltamivir carboxylate (OC), the main metabolite of tamiﬂu).
Concentrations of OC in catchments with low ﬂow and high populations are
predicted to be more than 20mg l−1, which may affect the function and stability
of WWTP (Singer et al. 2007, 2008).
Under normal conditions, the inputs of PhACs are generally considered to
be constant and widely distributed. However, for some pharmaceuticals (i.e.
antibiotics) differences between winter and summer inﬂuent loads were noted,
probably because of higher attenuation in summer and less use of pharmaceuticals
(Miao et al. 2004; Castiglioni et al. 2006a). On the other hand, for other
drugs (e.g. β-blockers, diuretics and anti-ulcer drugs) no seasonal variability
was observed.
The most ubiquitous drugs in WWTP inﬂuents are summarized in table 1,
together with their concentration ranges reported in the literature.
Generally, the highest concentrations are commonly reported for NSAIDs,
which could be attributed to their wide consumption because they can be
purchased without medical prescription (i.e. OTC drugs). For example, ibuprofen
is usually detected at very high concentrations (in μg l−1; Nakada et al. 2006;
Radjenovic et al. 2007; Santos et al. 2007; Terzic et al. 2008). Although the
percentage of elimination of this drug is very high, it is still detected in rivers
downstream WWTPs due to a very high usage in human medicine. Other very
popular pain killers are acetaminophen (paracetamol) and aspirin (acetyl-salicylic
acid). Besides these OTC drugs, pharmaceuticals ubiquitous in raw sewage
are also prescription drugs such as β-blockers (Vieno et al. 2006; Gros et al.
2007; Radjenovic et al. 2007). Atenolol seems to be the most frequently found
β-blocker worldwide in WWTP inﬂuents (Castiglioni et al. 2006a; Nikolai
et al. 2006). Numerous studies also revealed substantial presence of antibiotics
in the environment, due to their widespread consumption in human and
veterinary medicine. For example, Gros et al. (2007) found the macrolide
azithromycin, the sulphonamide sulphamethoxazole and trimethoprim in all
samples analysed at seven Spanish WWTPs and at considerable loads, followed
by the macrolide erythromycin and the ﬂuoroquinolone oﬂoxacin. The anti-
epileptic drug carbamazepine is one of the most prominent drugs with a long
history of clinical usage, and it is frequently found in the environment (Clara
et al. 2004a,b; Gros et al. 2007; Radjenovic et al. 2007). This drug has proved
to be very recalcitrant, as it bypasses sewage treatment. Lipid regulators are
ordinarily applied drugs in clinical practice, and they are used to lower the
level of cholesterol and regulate the metabolism of lipids. In all countries
with developed medical care, X-ray contrast media can be expected to be
present at appreciable quantities in sewage water. Clara et al. (2005) detected
iopromide at a mean concentration of 3.84μg l−1 in the inﬂuent of a WWTP
receiving hospital wastewater, while in WWTPs without a hospital within their
drainage area this contrast media was not present. Iodinated X-ray contrast
media are proved to contribute signiﬁcantly to the total absorbable organic
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Table 1. Occurrence of pharmaceutical residues in wastewater treatment plants inﬂuents.
compound inﬂuent concentration (μg l−1) reference
analgesics and anti-inﬂammatory drugs
ibuprofen 53.48–373.11; 150.73a Santos et al. (2007)
0.381–1.13; 0.672b Nakada et al. (2006)
2.6–5.7 Carballa et al. (2004)
8.45a; 16.5c Lishman et al. (2006)
23.4a Vieno et al. (2005)
34–168; 84a Gómez et al. (2007)
ketoprofen 0.108–0.369; 0.208b Nakada et al. (2006)
0.146a; 0.289c Lishman et al. (2006)
2.9a Vieno et al. (2005)
0.57c Tauxe-Wuersch et al. (2005)
0.16–0.97; 0.451a Gros et al. (2006)
naproxen 0.038–0.23; 0.1b Nakada et al. (2006)
1.8–4.6 Carballa et al. (2004)
8.6a Vieno et al. (2005)
5.58a; 17.1c Lishman et al. (2006)
diclofenac 0.204a; 1.01c Lishman et al. (2006)
0.46a Vieno et al. (2005)
3.25a; 4.114a; 3.19a; 1.4a; 0.905a Clara et al. (2005)
0.05–0.54; 0.25a Gros et al. (2006)
2.94c Tauxe-Wuersch et al. (2005)
indomethacin 0.23a; 0.64c Lishman et al. (2006)
n.d. Gros et al. (2006)
acetyl-salicylic acid 0.47–19.4; 5.49b Nakada et al. (2006)
salicylic acid 13.7a; 27.8c Lishman et al. (2006)
acetaminophen 0.13–26.09; 10.194a Gros et al. (2006)
29–246; 134a Gómez et al. (2007)
lipid regulator and cholesterol lowering statin drugs
gemﬁbrozil 0.453a; 0.965c Lishman et al. (2006)
n.d.–0.36; 0.155a Gros et al. (2006)
bezaﬁbrate 2.2a Vieno et al. (2005)
1.96a; 2.014a; 6.84a; 7.6a; 1.55a Clara et al. (2005)
n.d.–0.05; 0.023a Gros et al. (2006)
cloﬁbric acid n.d.–0.11; 0.072a Gros et al. (2006)
0.36c Tauxe-Wuersch et al. (2005)
psychiatric drugs
carbamazepine 0.015–0.27; 0.054b Nakada et al. (2006)
1.85a; 1.2a; 0.704a; 0.67a; 0.325a Clara et al. (2005)
n.d.–0.95; 0.42a Gros et al. (2006)
0.12–0.31; 0.15a Gómez et al. (2007)
antibiotics
sulphamethoxazole n.d.–0.87; 0.59a Gros et al. (2006)
oﬂoxacin n.d. Gros et al. (2006)
ciproﬂoxacin 3.8b; 4.6c Watkinson et al. (2007)
norﬂoxacin 0.17b; 0.21c Watkinson et al. (2007)
(Continued.)
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Table 1. (Continued.)
compound inﬂuent concentration (μg l−1) reference
trimethoprim 0.34b; 0.93c Watkinson et al. (2007)
n.d.–4.22; 1.172a Gros et al. (2006)
antihistamines
ranitidine n.d.–0.29; 0.188a Gros et al. (2006)
β-blockers
atenolol n.d.–0.74; 0.395a Gros et al. (2006)
(0.971± 0.03)a MacLeod et al. (2007)
metoprolol (0.411± 0.015)a MacLeod et al. (2007)
sotalol 0.12–0.2; 0.167a Gros et al. (2006)
(0.529± 0.01)a MacLeod et al. (2007)
propranolol 0.08–0.29; 0.168a Gros et al. (2006)
(0.01± 0.001)a MacLeod et al. (2007)
X-ray contrast media
iopromide 6.0–7.0 Carballa et al. (2004)
(7.5± 1.5)a Ternes & Hirsch (2000)
diatrizoate (3.3± 0.7)a Ternes & Hirsch (2000)
iopamidol (4.3± 0.9)a Ternes & Hirsch (2000)
aMean.
bMedian.
cMaximum concentrations.
iodine in clinical wastewaters; up to 130μg l−1 of iodine in the inﬂuent of
municipal WWTP in Berlin, and 10mg l−1 was detected in hospital sewage
(Oleksy-Frenzel et al. 2000).
According to the World Drug Report 2007, DA usage seems to be stabilized
now after the increasing trends observed over a decade; however, the amount
of people who still use illicit drugs each year globally accounts for 200 million
(UNODC 2007). Similar to pharmaceuticals, these substances are considered to
be ‘pseudo-persistent’ in the environment, thus they have become a group of
emerging environmental contaminants of interest. DAs reach aquatic systems
mainly through sewage water. After drug ingestion, diverse proportions of the
parent compound, conjugated forms and metabolites are excreted via urine and
ﬂushed towards municipal WWTPs. Some of them are not efﬁciently removed at
WWTPs and reach the aquatic environment via WWTP efﬂuents, which is their
main release pathway, as direct disposal is not a common practice. Neither their
fate in the aquatic environment nor their potential toxicological or cumulative
effects on the aquatic ecosystems have yet been studied.
Since 2004 several authors have developed analytical methodologies based
on liquid chromatography-tandem mass spectrometry (LC-MS/MS) to evaluate
the occurrence of DAs in sewage and natural waters: (Jones-Lepp et al. 2004;
Zuccato et al. 2005; Castiglioni et al. 2006b; Hummel et al. 2006; Boleda
et al. 2007; Bones et al. 2007; Huerta-Fontela et al. 2007; Kasprzyk-Hordern
et al. 2007, 2008; Gheorghe et al. 2008; Postigo et al. 2008a; Zuccato et al.
2008). These methods have been appropriately validated in terms of linearity,
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sensitivity, precision and accuracy and, since most of them rely on the use
of two selected reaction monitoring transitions per compound and deuterated
standards for quantiﬁcation by the internal standard method, the methods are
also highly selective and reliable (Postigo et al. 2008b). The target DAs and
metabolites studied so far belong to ﬁve different classes: cocainics, amphetamine-
like compounds, opiates, cannabinoids and lysergics. However, due to their recent
identiﬁcation as water contaminants (the ﬁrst report of their presence in water
dates from 2004 (Jones-Lepp et al. 2004), data on their occurrence in wastewater
are still scarce. Table 2 summarizes the mean concentration values reported so
far in the peer-reviewed literature. These values correspond to both inﬂuent and
efﬂuent wastewater samples collected from several European WWTPs located in
Spain (Boleda et al. 2007; Huerta-Fontela et al. 2007, 2008; Postigo et al. 2008a),
Ireland (Bones et al. 2007), Italy (Zuccato et al. 2005; Castiglioni et al. 2006b),
Switzerland (Castiglioni et al. 2006b), Belgium (Gheorghe et al. 2008), United
Kingdom (Kasprzyk-Hordern et al. 2008) and Germany (Hummel et al. 2006).
The ubiquity of the different target compounds is directly related to local
patterns of drug abuse. The highest loads are usually reported for two cocainic
compounds, namely cocaine (CO) and its main metabolite benzoylecgonine
(BE), that are commonly detected at the high nanograms per litre or even
the micrograms per litre level. The highest concentrations have been found
in inﬂuent waters collected at a WWTP located in Catalonia (Spain), where
cocaine and BE, an inactive metabolite of cocaine, were present at maximum
concentrations of 4700 and 7500 ng l−1 (Huerta-Fontela et al. 2008). Other cocaine
metabolites, namely cocaethylene, nor-cocaine and nor-benzoylecgonine, have
been investigated by some authors, but their levels have always been below
100 ng l−1 in inﬂuent waste waters.
Overall, opioids are present in water at lower concentrations than BE and
CO. Morphine (MOR), which has medical applications, is the opioid found at
the highest levels in WWTPs. Deconjugation of its major urinary metabolite
in waste water (morphine-3β-D-glucuronide, M3G) and degradation of other
opioids (e.g. heroin (HER) and its metabolite 6-acetylmorphine (6ACM)) may
contribute to increased MOR concentration in water, since these compounds
often go undetected or are detected at low concentrations, below 20 ng l−1
(Castiglioni et al. 2006b; Boleda et al. 2007; Postigo et al. 2008a). Regarding
methadone—the long-acting opioid agonist used for treating acute and chronic
pain and for detoxiﬁcation treatment of opioid addiction—is commonly present
in sewage waters at lower levels than its pharmacologically inactive metabolite,
2-ethylidene-1,5-dimethyl-3,3-di-phenylpyrrolidine (EDDP) (Castiglioni et al.
2006b; Boleda et al. 2007; Bones et al. 2007).
Amphetamine-like compounds, so-called ‘designer drugs’ (3,4-methylene-
dioxymethamphetamine (MDMA or ‘Ecstasy’), N -methyl-1-(1,3-benzodioxol-
5-yl)-2-butanamine (MBDB or ‘Eden’), 3,4-methylenedioxyethamphetamine
(MDEA or ‘Eve’) and 3,4-methylenedioxyamphetamine (MDA or ‘Love pills’),
have frequently been detected at the nanograms per litre level in the different
WWTPs studied. In the light of the reported results summarized in table 1,
amphetamine (AM) and methamphetamine (MA) are usually present at lower
concentrations than MDMA. Only high levels of AM (5236 ng l−1) were found in
inﬂuent sewage water collected at a WWTP in Wales, surpassing the levels found
for BE and CO in the same sample (Kasprzyk-Hordern et al. 2008).
Phil. Trans. R. Soc. A (2009)
 on October 22, 2010rsta.royalsocietypublishing.orgDownloaded from 
3988 M. Petrovic et al.
Concerning lysergic acid diethylamide (LSD) and its metabolites N -demethyl-
LSD (nor-LSD and nor-iso LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD), absence
or very low concentrations have been reported in inﬂuent samples. These results
are in line with the very low doses of LSD needed to produce an effect compared
with those needed in the case of other drugs (micrograms versus milligrams), as
LSD is the most potent psychoactive drug known to date.
The presence of 9-tetrahydrocannabinol (THC), which is the most
psychologically active constituent of cannabis (the most widely used illicit
drug), in inﬂuent sewage waters has been observed insigniﬁcantly when
compared with that of its metabolites since THC is extensively metabolized
before excretion. 11-Nor-9-carboxy-D9-tetrahydrocannabinol (nor-THC) and
11-hydroxy-D9-tetrahydrocannabinol (OH-THC) have been found at levels below
100 and 50 ng l−1, respectively.
Measured values of DAs in sewage waters provide real-time data to estimate
drug abuse at the community level. This strategy was ﬁrst proposed by Daughton
(2001) in 2001 and implemented 4 years later by Zuccato et al. (2005) to estimate
cocaine abuse in the north of Italy. Such estimations, obtained in a fairly cheap
and anonymous way (avoiding potential privacy conﬂicts), are useful to adopt
immediate measures to ﬁght drug abuse.
3. Removal in conventional activated sludge treatment
After administration, both PhACs and DAs can be excreted as an unchanged
parent compound, in the form of metabolites or as conjugates of glucuronic and
sulphuric acid, primarily via urine and faeces. Their removal in conventional
WWTPs is variable and dependent on the properties of the substance and on
the treatment process applied and is potentially affected by several factors such
as sludge retention time (SRT), hydraulic retention time (HRT) and temperature
(Suárez et al. 2008).
(a) Pharmaceuticals
The most important pathways for removal of PhACs during wastewater
treatment are biotransformation/biodegradation and abiotic removal by
adsorption to the sludge. Considering the low values of Henry coefﬁcients (KH) of
most of the PhACs detected in wastewater streams, stripped fractions removed by
volatilization can be neglected (Joss et al. 2006). The efﬁciency of their removal at
WWTP depends on their physico-chemical properties, especially hydrophobicity
and biodegradability, and process operating parameters (i.e. HRT, SRT and
temperature). Higher SRT will allow the enrichment of slowly growing bacteria,
and hence a more diverse microbial biocenosis will be established than with lower
SRT. If a PhAC is biodegradable and if this degradation can be described by
Michaelis–Menten kinetics, then critical SRT can be determined below which no
biological removal of a substance occurs (Clara et al. 2005). If a compound is
present only at trace levels of concentration (nanograms per litre, lower range
of micrograms per litre), it will probably be transformed by co-metabolism (i.e.
mixed substrate growth), whereas speciﬁc SRT of such trace organics will depend
on the maximum speciﬁc growth rate (μmax) on primary substrate. The nature of
microbial population can have a signiﬁcant impact on the biodegradation of some
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Figure 1. Total loads of pharmaceuticals measured, expressed as g d−1 per 1000 inhabitants, in
the seven Spanish WWTPs and the RRs reported for each plant. I, inﬂuent; E, efﬂuent; HRT,
hydraulic retention time. Adapted from Gros et al. (2007).
persistent PhACs. For example, it was found that longer SRT that provide growth
of nitrifying bacteria is favourable for degradation of antibiotic trimethoprim
(Batt et al. 2006). Clara et al. (2005) reported a correlation between the observed
removal of ibuprofen and bezaﬁbrate and the operating SRT. NSAID ibuprofen
is considered to be easily degraded in the environment, and removal rates (RRs)
traditionally reported in the literature were in the range of 80–100%. On the other
hand, HRT can more seriously affect compounds with a moderate degradation
velocity leading to better elimination of such compounds at higher HRT. Figure 1
shows the total load of 29 pharmaceuticals detected in seven Spanish WWTPs,
as well as the RRs for each WWTP in correlation to the HRT (Gros et al. 2007).
Contradictory results have been reported for the removal of NSAID diclofenac
during CAS wastewater treatment. No inﬂuence of the increased SRT on its
biodegradation was found (Clara et al. 2005). In some WWTPs attenuation
of 50–70% of diclofenac was reported (Ternes 1998; Thomas & Foster 2005;
Castiglioni et al. 2006a; Radjenovic et al. 2007). In contrast, many studies
showed extremely low efﬁciency of conventional treatment (only 10–30% removal;
Lindqvist et al. 2005; Joss et al. 2005).
Unexplained variations of concentration over time were also observed for
lipid regulator bezaﬁbrate (Lindqvist et al. 2005) and sulphonamide antibiotics,
probably because of deconjugation processes that may occur during contact
with activated sludge. For example, a signiﬁcant amount of sulphamethoxazole
enters WWTPs in metabolized form as N4-acetyl-sulphamethoxazole that can be
converted back to the original compound (Göbel et al. 2004).
Many authors reported poor elimination of the anti-epileptic drug
carbamazepine (Metcalfe et al. 2003; Clara et al. 2004a,b, 2005; Joss et al.
2005; Radjenovic et al. 2007). Pharmacokinetic data indicate that only 1–2%
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Figure 2. Average removal efﬁciencies (per cent) calculated for various DAs and metabolites
monitored by Postigo et al. (2008a) in four Spanish WWTPs. Black bars are used to highlight
analytes that have shown occasionally negative eliminations (counted as 0 removal when calculating
average values).
of carbamazepine is excreted unmetabolized. However, glucuronide conjugates
of carbamazepine can presumably be cleaved in the sewage, and thus increase
its environmental concentrations (Ternes 1998). This is conﬁrmed by its high
ubiquity in the environment at concentration levels of several hundred nanograms
per litre in different surface waters. Due to its recalcitrant nature, it can
be used as an anthropogenic marker for the contamination of the aquatic
environment.
(b) Illicit drugs
Efﬁciency of removal of DAs in WWTPs is largely unknown and should be
addressed in order to control their release to the environment and avoid potential
adverse effects in the aquatic ecosystem. Removal values of DAs reported so far
refer to the elimination of these compounds by conventional activated sludge
processes. No peer-reviewed literature on their elimination in MBRs or by river
bank ﬁltration has been found.
Most of the investigated DAs and metabolites are hydrophilic analytes;
therefore they are expected to be predominantly present in the dissolved aqueous
phase and to adsorb poorly onto solid particles. As an exception, cannabinoids,
with octanol–water partition coefﬁcients higher than 5, are expected to be
predominantly found in sewage sludge.
The compounds investigated present different elimination rates, which differ
also between WWTPs. As can be observed in table 2, concentrations of DAs
and metabolites are in general lower by 1–3 orders of magnitude in efﬂuent
than in inﬂuent wastewater samples. This indicates good degradation or sorption
to sludge during conventional wastewater treatment. Figure 2 summarizes the
average removals calculated for various DAs and metabolites in a study conducted
by Postigo et al. (2008a) in four Spanish WWTPs. As can be observed, average
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eliminations varied from 17.5 per cent for THC-COOH to 96 per cent for BE.
Black bars correspond to analytes that were occasionally detected at higher levels
in efﬂuent than in inﬂuent waters.
Overall, cocainic compounds have shown high removal percentages.
Huerta-Fontela et al. (2008) reported a removal higher than 88 per cent for
cocaine and benzoylecgonine after investigation of several WWTPs located in
Catalonia (Spain). Good elimination of benzoylecgonine (93%) was also observed
by Bones et al. (2007) in an Irish WWTP; however, a worse value was reported for
cocaine (72%). The results obtained by Postigo et al. (2008a) indicate an average
elimination of 95 per cent for CO, BE and cocaethylene. In this study, removals
ranging from 67 to almost 100 per cent, from 69 to almost 100 per cent and from
66 to 98 per cent were observed for cocaine, benzoylecgonine and cocaethylene,
respectively.
Overall, lower removals compared with cocainic compounds have been observed
for opioids. Average removals of 72, 74 and 86 per cent have been calculated
from the results reported by Postigo et al. (2008a) for 6ACM, HER and MOR,
respectively. Good removal of MOR was also observed by Hummel et al. (2006),
as MOR concentration was reduced by a factor of 8 from inﬂuent to efﬂuent
waters. However, according to the results published by Boleda et al. (2007),
the average MOR elimination in various Spanish WWTPs reached only 38 per
cent, and the rest of the studied opioids (nor-MOR, methadone, EDDP, HER
and 6ACM) were not or very poorly eliminated, showing two of the WWTPs
investigated had higher concentrations for methadone and EDDP in efﬂuent than
in inﬂuent waters. MOR is excreted in urine mainly as glucuronide metabolites;
however, cleavage of the conjugated molecules in wastewater is likely to occur
in the light of the low levels found for M3G (the only conjugated compound
studied) in comparison with those usually detected for MOR (Castiglioni
et al. 2006b).
Removal of amphetamine-like compounds (AM, MA, MDMA, MDA) in
Spanish WWTPs was between 40 and 99 per cent according to Huerta-Fontela
et al. (2008) and 65 per cent on average according to Postigo et al. (2008a).
Among all investigated amphetamine-like compounds, MDMA provides the worst
elimination values and the highest loads of this type of analytes in efﬂuent
samples, with occasionally higher values in efﬂuent than in inﬂuent samples
(Postigo et al. 2008a). Also, negative eliminations, in this case for MDA, have
been reported by Castiglioni et al. (2006b) and Huerta-Fontela et al. (2008), which
could be related to N -demethylation processes of MDMA during wastewater
treatment.
The results reported by Postigo et al. (2008a) for LSD and its metabolites
point at an average removal of 72 per cent; with variations from 45 to almost 100
per cent depending on the compound and WWTP, and occasionally higher (in the
low nanograms per litre range) concentrations in efﬂuent than in inﬂuent waters.
Concerning cannabinoids, a metabolite of THC, namely nor-THC, has been
observed to be poorly removed by conventional wastewater treatment processes,
as several authors have reported higher levels in efﬂuent waters than in inﬂuents
(Boleda et al. 2007; Postigo et al. 2008a). This phenomenon has been less
frequently observed for the other investigated THC metabolite (OH-THC);
however, removals under 50 per cent have usually been reported for this
compound and the parent drug THC.
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4. Removal by membrane bioreactor wastewater treatment
The upgrading of WWTPs and implementation of sustainable technologies
impose as possible solutions for the safe reclamation of high-quality treated
efﬂuent. One of the advanced technologies that has been gaining interest over
the last 25 years is MBR. The MBR technology integrates biological degradation
of organic matter present in wastewater with membrane ﬁltration, thus surpassing
the limitations of the conventional CAS treatment (e.g. limited operational SRT,
sludge-settling characteristics). MBR has become a technically and economically
feasible alternative for water and wastewater treatment, especially because of
high SRTs achieved within compact reactor volumes. Due to high biomass
concentration the degradation rate is higher, and also specialists are grown
for problematic compounds. Therefore, MBR sludge is expected to have higher
biodegradation potential for trace organic contaminants for several reasons:
more diversiﬁed microbial population, better acclimation of micro-organisms to
substrate and larger fraction of active biomass.
Several studies (Lesjean et al. 2005; Quintana et al. 2005; Göbel et al. 2007;
Radjenovic et al. 2007; Reif et al. 2008) conﬁrmed an advantage of MBR
over CAS when reduction of pharmaceutical residues is concerned. For most of
the investigated PhACs, MBR efﬂuent concentrations were usually signiﬁcantly
lower than in the efﬂuent of a conventional treatment. They are removed
from wastewater during membrane treatment by sorption, degradation or a
combination of both. Better removal of readily biodegradable micropollutants in
the MBR could be due to a smaller ﬂock size of sludge, which enhances mass
transfer by diffusion and therefore increases the elimination. Considering the
composition of sludge originating from an MBR (specialized micro-organisms,
large portion of active biomass in suspended solids) improved removal is to be
expected. In general, no relationship has been found so far between the structures
of micropollutants and their removal during wastewater treatments.
Radjenovic et al. (2007, submitted) found improved removal of the majority of
target compounds (ﬁgure 3). Kimura et al. (2005) reported greater attenuation of
inﬂuent concentrations of ketoprofen, mefenamic acid and naproxen, which was
explained by better adaptation of MBR microbial consortia to these compounds.
Lesjean et al. (2005) also correlated an improved removal in the MBR to the
enrichment of specialized micro-organisms.
MBR technology is generally considered as suitable for the treatment of
wastewater containing refractory compounds. However, some compounds such
as the anti-epileptic drug carbamazepine pass through both WWTPs and
MBRs without any reduction. Moreover, in many cases signiﬁcantly higher
concentrations in the efﬂuent were recorded, which could be explained by
the presence of input conjugate compounds of carbamazepine that are being
retransformed during treatment into the original compounds. NSAID diclofenac
and the lipid regulator cloﬁbric acid were also found to be slightly recalcitrant
pharmaceutical residues in some studies. Kimura et al. (2005) related the
persistence of diclofenac and cloﬁbric acid in both MBR and CAS processes to
the presence of chlorine in their structures, which makes them barely degradable.
González et al. (2006) also suggested that faster diminution of diclofenac was
because of better acclimation of micro-organisms to the MBR inﬂuent water.
Radjenovic et al. (2007) noted a signiﬁcant improvement in the removal of
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Figure 3. Comparison of the mean removal of encountered pharmaceuticals in full-scale CAS
and pilot-scale MBRs. The eliminations presented for MBR are given as mean values of
the removal of each compound obtained in two pilot-scale MBR (one with hollow ﬁbre
membrane and another with ﬂat-sheets). 1, naproxen; 2, ketoprofen; 3, ibuprofen; 4, diclofenac;
5, indomethacin; 6, acetaminophen; 7, mefenamic acid; 8, propyphenazone; 9, ranitidine; 10,
loratidine; 11, carbamazepine; 12, oﬂoxacin; 13, sulphamethoxazole; 14, erythromycin; 15, atenolol;
16, metoprolol; 17, hydrochlorothiazide; 18, glibenclamide; 19, gemﬁbrozil; 20, bezaﬁbrate;
21, famotidine; 22, pravastatin; 23, sotalol; 24, propranolol; 25, trimethoprim. Adapted from
Radjenovic et al. (2008).
these compounds when using an MBR unit. Eliminations in MBR of diclofenac
and cloﬁbric acid were 87 and 72 per cent, compared with 50 and 28 per
cent found in CAS, respectively. Besides possible changes in microbial consortia
during adaptation to wastewater contaminants, another explanation for the
better performance of MBR could be its enhanced elimination by sorption. Since
sorption processes are relevant for diclofenac (Suárez et al. 2008), and keeping in
mind that MBR sludge has higher organic matter content which means higher
sorption potential, the amount of the adsorbed compound can be expected to be
greater than in the CAS system.
Theoretically, the increase in SRT should have a positive inﬂuence on the
biodegradation of organic micropollutants. In a study of Göbel et al. (2007),
a clear increase in attenuation percentages was observed at sludge ages of
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60–80 days for the antibiotics trimethoprim, azithromycin, erythromycin and
clarythromycin, whereas higher reduction of roxythromycin occurred already at
33 days SRT. Drastic improvement in the elimination of mefenamic acid was
also observed for the laboratory-scale MBR operating with long SRT (greater
than two months; Radjenovic et al. 2007). Kimura et al. (2007) noticed an
improvement in the MBR operating with extremely aged sludge (i.e. SRT=65
days) where 90 per cent elimination was achieved, which was assigned mainly
to the biodegradation removal pathway. However, Joss et al. (2005) found no
improvement in degradation of roxythromycin and some other PhACs with
increased SRT. They noted a comparable performance of CAS and a pilot-scale
MBR process run in parallel regarding removals of several selected PhACs (i.e.
ibuprofen, naproxen, diclofenac, carbamazepine and roxythromycin).
5. Removal by riverbank ﬁltration
At present, surface water is certainly not enough to cope with the water
requirement for agricultural, industrial, recreational and drinking purposes. In
this context, the usage of groundwater has become essential; therefore, their
quality and quantity has to be carefully managed. Induced recharge of aquifers
can guarantee a sustainable level of groundwater, while strict quality control of
waters intended for recharge will minimize contamination of both the groundwater
and the aquifer area. However, all water resources available are threatened by
multiple sources of contamination from the extended use of chemicals worldwide.
In this respect, the environmental occurrence of organic micropollutants such
as pesticides, pharmaceuticals, industrial chemicals and their metabolites has
experienced fast-growing interest (Heberer 2002; Hiemstra et al. 2003).
Bank ﬁltration is a type of ﬁltration that puriﬁes water by passing the water
through the banks of a river or lake. It is then extracted by wells located some
distance away from the water body. This purifying approach has been in use in
Europe, especially in Germany along the Rhine, since the 1870s. Major facilities
also exist in many other countries, including the USA, where Nebraska is leading
the use of such facilities.
In this section an overview of the pharmaceutical and illicit drug residues found
to be present in the waters involved in bank-ﬁltration practices at managed
aquifer recharge sites as well as the potential of this approach as an efﬁcient
method for the mitigation of such pollutants is presented.
(a)Groundwater contamination
Aquifer systems as environmental compartments are substantially different
from other aqueous systems. Long residence times, low temperatures, low degrees
of dilution and decreased microbial population are factors favouring the long-
term fate of organic micro-contaminants in groundwater. The primary concern
regarding contaminants input is the removal of pathogenic micro-organisms;
however, trace metals and organic compounds are also important issues. When
organic contaminants are introduced into an aquifer, they will either move with
the water or be adsorbed on the solid surfaces. Whenever retained contaminants
do not break down they will accumulate in the aquifer. This accumulation may
have long-term impacts.
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Reclaiming an aquifer that has been contaminated is a difﬁcult, long and
expensive process; therefore, a prerequisite of induced recharge is that it
should not risk the quality of the groundwater resource. It is well known that
hydrogeology inﬂuences the fate and transport of organic micro-contaminants.
Factors such as depth to water table, sediment porosity and permeability, and
groundwater ﬂow control how fast and to what extent contaminants make their
way from the recharge point to the recovery point. Geochemical and nutrient
conditions also drive the fate of organics into the aquifer, with low dissolved
oxygen/low nutrient conditions favouring long-term persistence.
(b) Fate
Surface water used for the inﬁltration at bank ﬁltration sites is often
contaminated with pharmaceutical residues and their metabolites as a
consequence of discharges from municipal WWTP efﬂuents, where they are not
effectively removed (Verstraeten et al. 2002). In a recent review (Díaz-Cruz &
Barceló 2008), an overview of the pharmaceuticals, pesticides and industrial
chemicals found to be present in inﬁltrated and ground waters was published.
Table 3 lists some of the most frequently detected pharmaceuticals in surface
waters that are transferred to the aquifer area and the supply water.
The transport and fate of six pharmaceuticals belonging to different
prescription classes, carbamazepine, primidone, bezaﬁbrate, indomethacine,
diclofenac and propyphenazone, and two drug metabolites, cloﬁbric acid,
and 1-acetyl-1-methyl-2-dimethyl-oxamoyl-2-phenylhydrazide (AMDOPH; a
metabolite of dimethylaminophenazone), were detected in waters from recharging
ponds and control wells and six of them persisted in the drinking water supply
in bank-ﬁltration sites in Berlin (Germany), replenishing groundwater from lakes
Tegel and Vannsee (Heberer et al. 2004; table 3).
Heberer et al. (2008) recently evaluated the behaviour of antibiotic residues
during bank ﬁltration in Berlin. Anhydroerothromycin, clindamycin and
sulphamethoxazole were the three analytes detected in the ﬁltrate out of
the seven antibiotics detected in the surface water used for recharge. Only
sulphamethoxazole was further detected in the abstracted water. A higher mean
concentration of 118 ng l−1 sulphamethoxazole has been reported in the drinking
water extracted from the production well in a recharge facility at Lake Tegel
(Grünheid et al. 2005). The analgesic diclofenac (Heberer et al. 1997; Sacher &
Brauch 2000) and the lipid regulator bezaﬁbrate (Heberer et al. 2001) were also
detected in ground water at low concentrations.
Hospital wastewater efﬂuents contain, in addition to residues of typical
prescription drugs, certain pharmaceutical compounds in hospital use, such as
X-ray contrast media. According to Ternes & Hirsch (2000), these contrast media
constitute the main fraction of the absorbable organic iodine in waters. Such
compounds are very polar, persistent in the aquatic environment and have been
found to be recalcitrant in wastewater treatments. Therefore, compounds such
as diatrizoate, iopromide, iopamidol and amidotrizoic acid were detected up to
the micrograms per litre concentration level in ground and inﬁltrated waters
(Putschew et al. 2000; Sacher & Brauch 2000; Ternes & Hirsch 2000). Recently,
the iodinated X-ray contrast agent iopromide has been searched for in extracted
raw water from monitoring and production wells of a bank ﬁltration site and
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Table 3. Mean concentrations (ng l−1) of pharmaceuticals in surface, inﬁltrated and supply waters
when surface water is used for groundwater-enhanced recharge in drinking water supply. n.r., not
reported; n.d., not detected.
conc. in conc. in conc. in
surface inﬁltrated supply
compound water water water reference
diclofenac 15a < 5a 35a Heberer et al. (2004)
25b 30b < 5a
cloﬁbric acid 40a < 5a 50a Heberer et al. (2004)
60b 25b 115b
propyphenazone 230a 170a 240a Heberer et al. (2004)
145b 85a 30b
AMDOPH 355a 465a 1250a Heberer et al. (2004)
170b 115b 280b
carbamazepine 110 110 n.r. Brauch et al. (2000)
325a 365a 60a Heberer et al. (2004)
330b 215b 15b
primidone 55a 40a 40a Heberer et al. (2004)
60b 70b 10b
indometazine n.d.a n.d.a n.d.a Heberer et al. (2004)
15b < 5b n.d.b
bezaﬁbrate 20a n.d.a < 5a Heberer et al. (2004)
60b 10b n.d.b
iopromide 841 151 n.r. Grünheid et al. (2005)
sulphamethoxazole 485 122 n.r. Grünheid et al. (2005)
151 43 2 Heberer et al. (2008)
acetyl-sulphamethoxazole 7 n.d. n.d. Heberer et al. (2008)
clarythromycin 8.9 n.d. n.d. Heberer et al. (2008)
roxythromycin 11 n.d. n.d. Heberer et al. (2008)
anhydroerithromycin 50 50 n.d. Heberer et al. (2008)
clindamycin 31 n.d. n.d. Heberer et al. (2008)
aData from Lake Tegel.
bData from Lake Vannsee.
one artiﬁcial recharge site at Lake Tegel (Grünheid et al. 2005); however, in
both production wells concentrations found were below the limit of quantiﬁcation
(<20 ng l−1).
(c) Removal
Several mechanisms including adsorption, dispersion and biological
transformations (within the ﬁrst few meters of inﬁltration) are the main processes
driving the attenuation and fate of organic contaminants in groundwater
environments during inﬁltration (Roberts & Valocchi 1981); however, these
processes are not yet sufﬁciently understood. Different patterns and kinetics for
the removal of the trace organic compounds can be found; however, there is a
general agreement that signiﬁcant improvement is achieved in the quality of the
recovered waters.
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Redox processes in enhanced groundwater enrichment sites are known to affect
the elimination of pharmaceutical residues. These processes are known to be
temperature-dependent, since these processes are in general catalysed microbially
and temperature variations inﬂuence the microbial activity (Prommer &
Stuyfzand 2005). Under warmer temperatures (greater than 14◦C) anoxic
conditions prevail, while below 14◦C oxic conditions develop. Recent studies
investigated the impact of the inﬁltration water temperature on the redox
degradation of carbamazepine, phenazone and phenazone-like pharmaceuticals
in Berlin. Outcomes evidenced that removal during inﬁltration was not observed
for carbamazepine, irrespective of its redox state; meanwhile different degradation
rates were shown by the rest of compounds under aerobic conditions (Greskowiak
et al. 2006). These results are in concordance with the poor mitigation, reported
by several authors, of carbamazepine and another antiepileptic drug, such as
primidone, which were found to be present in ground and drinking water where
inﬁltration was carried out (Heberer et al. 2001; Preuss et al. 2002; Mansell &
Drewes 2004; Massmann et al. 2008a,b).
In the same study other antibiotics and X-ray contrast agents such as iopromide
also show redox-dependent mitigation. Clindamycin was found to be almost
completely eliminated under anoxic conditions. Sulphamethoxazole could be
reduced to ca 25 per cent of the surface concentration by bank ﬁltration; however,
only inﬁltration basins were able to degrade it to half (Grünheid et al. 2005;
Heberer et al. 2008). Other antibiotics investigated, namely clarythromycin,
roxythromycin and anhydroerithromycin, were found to be readily removable by
bank ﬁltration, despite the redox conditions (Heberer et al. 2008). For the X-ray
contrast medium iopromide results indicate that removal rates at both sites are
around 82 and 89 per cent, respectively, which is in concordance with the rapid
degradation observed under both aerobic and anoxic conditions but only partially
dehalogenated under anoxic conditions observed by Grünheid et al. (2005) during
bank ﬁltration.
Some laboratory and ﬁeld experiments on inﬁltration processes evidenced
signiﬁcant removal of diclofenac and bezaﬁbrate in the inﬁltration process as
a result of their tendency to be both adsorbed on the soil/sediment (Heberer
et al. 2001, 2004; Ternes et al. 2007) and transformed during passage (Scheytt
et al. 2007). According to Preuss et al. (2002), the elimination of bezaﬁbrate
along with diclofenac and ibuprofen would be in the range 60–80%. Cloﬁbric
acid, according to several authors, exhibited low mitigation, since little or no
adsorption and only very low degradation was observed during the soil passage
(Scheytt et al. 2001; Mersmann et al. 2002; Scheytt et al. 2007; Ternes et al. 2007;
Massmann et al. 2008a).
6. Conclusions
Due to their beneﬁcial health effects and economic importance, the reduction
of drug inputs into the environment through restricting or banning their use
is not possible. Moreover, the use of pharmaceutical compounds is expected
to grow with the increasing age of the population. The only possible way is
to regulate their environmental pathways, perhaps at source through labelling
of medicinal products and/or developing disposal and awareness campaigns.
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Another option is to add sewage treatments in hospitals, and to enhance current
wastewater treatment techniques in order to eliminate such polar pollutants more
efﬁciently.
MBR technology is considered the most promising development in
microbiological wastewater treatment. Several studies clearly outlined the strong
potential of MBR technology in reducing ecological risks associated with PhACs,
as well as other polar micropollutants. However, MBR technology is sometimes
seen as high risk and prohibitively costly compared with CAS and other more
established technologies. Further improvement of the process will increase its cost-
effectiveness and MBR technology is expected to play a key role in wastewater
treatment in the coming years, where it may ensure enhanced elimination and
biodegradation of PhACs, thus reducing the environmental risk posed by those
compounds.
Bank ﬁltration is an efﬁcient approach for the attenuation of most
pharmaceutical residues allowing a partial (propyphenazone, diclofenac,
sulphamethoxazole) or a total removal (bezaﬁbrate, indomethazine, steroids).
However, special attention must be paid when residues of carbamazepine or other
antiepileptic drugs, such as primidone, are present in the water intended for bank
ﬁltration, since no signiﬁcant removal is observed, but just a slight decrease in
the concentration as a consequence of the dilution with uncontaminated water.
However, bank ﬁltration does not guarantee the complete removal of all potential
pharmaceutical residues present in the water and can be regarded as a useful
tool for the pretreatment of raw water (wastewater, surface water and reclaimed
water) but is not sufﬁcient for a complete water treatment and requires further
puriﬁcation to produce drinking water.
This work has been supported by the EU project INNOVA-MED (INCO-CT-2006-517728) and
by the Spanish Ministry of Science and Innovation Projects CTM2007-30524-E and CEMAGUA
(CGL2007-64551).
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